曲美他嗪治疗2型糖尿病合并心力衰竭的疗效观察

目的探讨曲美他嗪治疗2型糖尿病合并心力衰竭的疗效观察。方法90例2型糖尿病合并心力衰竭患者按入院先后随机分为治疗组和对照组各45例，常规治疗控制血糖，治疗组给予曲美他嗪20mg，每日3次，疗程6个月。观察两组治疗前后左室舒张末期内径（LVEDD）、左室收缩末期内径（LVESD）及左室射血分数（LVEF）等变化。结果治疗后治疗组总有效率86．7％，明显优于对照组的68．9％（χ^2=3．521，P〈0．05）；两组治疗后LVEDD、LVESD较治疗前明显缩小（P〈0．05），LVEF较治疗前明显升高（P〈0．05）；治疗后治疗组LVEDD、LVESD较对照组明显缩小（P．〈0．05），LVEF较对照组明显升高（P〈0．05）。结论曲美他嗪能明显改善糖尿病合并心力衰竭患者的左心功能。

Effects of trimetazidine on cardiac function in type 2 diabetes mellitus patients with heart failure

Objective To study the effects of trimetazidine on cardiac function in type 2 diabetes mellitus patients with heart failure. Methods Ninty type 2 diabetes mellitus patients with heart failure were randomly divided into two groups (45 patients in control group,45 patients in treatment group). All patients in both two groups received routine therapy in order to have blood glucose under control,the treatment group was treated with trimetazidine 20mg po Tid ,treatment for 6 months. Before and after treatment ,two groups were detected left ventricular end-diastolic diameter (LVEDD), left ventricular end systolic diameter (LVESD) and left ventricular ejection fraction (LVEF), and the clinical efficacy were evaluated. Results Ater treatment, the rate of total efficiency was 68. 9% in control group, and it was 86. 7% in treatment group. The clinical efficacy of treatment group was significantly better than control group(P＜0.05) ;Ater treatment,LVEDD,LVESD were significantly reduced than those before treatment(P ＜0.05) ,LVEF was significantly higher than that before treatment (P ＜0.05);After treatment,LVEDD, LVESD in treatment group was significantly reduced than those in control group, LVEF was significantly higher than control group (P ＜ 0.05).Conclusion Trimetazidine can significantly improve the cardiac function in type 2 diabetes mellitus patients with heart failure.